Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-HIGH: Niacin Plus Statin for Vascular Events
NCT00120289Phase 3Terminated
- Sponsor
- Axio Research
- Start
- Sep 2005
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of niacin in atherogenic dyslipidemia (AD) (2 arms), sponsored by Axio Research. Primary endpoint: Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization at 36 months. Started Sep 2005; status: terminated.
02
Drugs
niacin
03
Conditions
atherogenic dyslipidemia (AD)
Beyond the preview
Go deeper on NCT00120289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120289.